This article is informational and not medical advice. Substance use during pregnancy requires immediate consultation with an OB/GYN and addiction medicine specialist. Do not attempt to stop substances abruptly during pregnancy without medical supervision — this can be dangerous for mother and baby.
Substance use during pregnancy represents one of the highest-urgency situations in addiction medicine — not only for the mother’s health but for fetal health and development. The interaction of substances with pregnancy physiology, fetal development, and obstetric risk requires specialized clinical management that goes beyond standard addiction treatment. This is an area where Oceánica’s honest practice is to provide clear guidance about when specialized programs in the U.S. are the appropriate care setting — and what those programs provide.
WHY PREGNANCY CHANGES TREATMENT
Pregnancy fundamentally changes the clinical calculus of addiction treatment in several important ways.
Fetal health as a primary concern:
The developing fetus is directly affected by maternal substance use — through placental transfer of substances, through the physiological effects on the intrauterine environment, and through the effects on fetal neurodevelopment. This makes substance use during pregnancy a two-patient situation, with fetal wellbeing as a co-primary clinical concern.
The danger of abrupt cessation:
One of the most important clinical points about addiction treatment during pregnancy is that abrupt cessation of certain substances is not safe — it can be more dangerous than continued use. Specifically:
- Abrupt alcohol cessation in a physically dependent pregnant woman carries seizure and cardiovascular risk to the mother and hemodynamic risk to the fetus.
- Abrupt opioid cessation (without MAT) during pregnancy carries significant risk of fetal distress and miscarriage/preterm labor due to withdrawal-associated stress on the fetus.
This is why self-managed “cold turkey” cessation during pregnancy is medically contraindicated — and why medical supervision is non-negotiable.
Obstetric risk overlay:
Substance use during pregnancy is associated with elevated obstetric risks — preterm labor, placental abruption, preeclampsia, growth restriction, and stillbirth risks that vary by substance. Ongoing obstetric monitoring during treatment is essential.
SUBSTANCES ESPECIALLY DANGEROUS IN PREGNANCY
Different substances carry different risk profiles during pregnancy, and the treatment approach varies accordingly.
Opioids:
Opioid use during pregnancy is associated with neonatal opioid withdrawal syndrome (NOWS), low birth weight, and other complications. However, abrupt opioid cessation during pregnancy carries significant fetal risk. The evidence-based approach is medication-assisted treatment with buprenorphine or methadone — which provides opioid stability for both mother and fetus, dramatically reduces the risk of relapse and overdose, and produces better obstetric outcomes than opioid cessation or continued illicit use. All medication decisions must be made by qualified physicians specializing in addiction medicine and obstetrics.
Alcohol:
Alcohol is the leading preventable cause of intellectual disability and developmental disorders (fetal alcohol spectrum disorders). There is no established safe level of alcohol consumption during pregnancy. Alcohol cessation under medical supervision is the goal; as noted, abrupt cessation in a physically dependent pregnant woman requires medical management of withdrawal.
Stimulants (cocaine, methamphetamine):
Associated with placental abruption, preterm birth, low birth weight, and possible neurodevelopmental effects. No FDA-approved medication exists for stimulant use disorder; behavioral treatment is the primary approach.
Cannabis:
Increasingly used but associated with low birth weight, preterm birth, and possible neurodevelopmental concerns. The “it’s natural” framing doesn’t apply to pregnancy — cannabis use during pregnancy is not considered safe by ACOG or major obstetric organizations.
Benzodiazepines:
Physical dependence on benzodiazepines during pregnancy requires careful, medically supervised tapering — abrupt cessation carries serious risk. Fetal benzodiazepine exposure raises concerns about cleft palate and neonatal withdrawal.
WHERE TO FIND PREGNANCY-SPECIALIZED CARE
Oceánica’s residential program is not equipped for pregnant patients because the specialized obstetric medical infrastructure — OB/GYN monitoring, labor and delivery capacity, perinatal addiction specialists — that pregnant patients require is not available at the Oceánica facility. For pregnant women with substance use disorders, specialized perinatal treatment programs in the U.S. are the appropriate care setting.
What perinatal treatment programs provide:
- OB/GYN care integrated with addiction treatment.
- Obstetric monitoring throughout the pregnancy.
- Perinatal addiction medicine specialists.
- Social work for child welfare navigation.
- MAT management that accounts for the pharmacokinetic changes of pregnancy.
- Postpartum planning and newborn assessment.
Finding perinatal treatment programs:
SAMHSA’s treatment locator (findtreatment.gov) allows searching for treatment programs that serve pregnant women. Filtering for “pregnant/postpartum women” in the specialty filter identifies programs with this specialized capacity.
State Opioid Treatment Authorities (SOTAs) can also provide referrals to perinatal treatment programs in each state.
MAT DURING PREGNANCY
Medication-Assisted Treatment during pregnancy deserves specific attention because it is the standard of care for opioid use disorder in pregnant women — and is still misunderstood by many patients and families.
The evidence:
Major medical organizations — ACOG (American College of Obstetricians and Gynecologists), ASAM (American Society of Addiction Medicine), and SAMHSA — all recommend MAT with buprenorphine or methadone as the standard of care for opioid use disorder during pregnancy. The evidence shows:
- MAT reduces fetal opioid withdrawal severity compared to untreated opioid use.
- MAT reduces obstetric complications compared to continued illicit opioid use.
- MAT reduces the risk of maternal overdose.
- MAT-exposed newborns can have neonatal withdrawal (neonatal abstinence syndrome) that is treatable.
The alternative of abrupt opioid cessation during pregnancy has a worse evidence profile than continued MAT — which is why the recommendation is MAT, not cessation.
Buprenorphine vs methadone during pregnancy:
Both are used. Buprenorphine has become increasingly preferred because of its more manageable pharmacology. Methadone has the longer evidence base. The choice depends on clinical circumstances and must be made by qualified physicians specializing in perinatal addiction medicine.
POSTPARTUM CONTINUATION
The postpartum period carries specific risks for women in recovery from addiction.
Postpartum relapse risk:
The postpartum period is a high-risk time for relapse — the physical and emotional demands of new parenthood, sleep deprivation, hormonal changes, and the potential for postpartum depression create vulnerability. Robust postpartum continuing care planning is essential.
MAT continuation:
Buprenorphine and methadone can generally be continued during breastfeeding, with guidance from the prescribing physician. This continuity of MAT through the postpartum period supports recovery stability.
Child welfare involvement:
In many states, substance use during pregnancy triggers mandatory reporting to child welfare agencies. Understanding this reality — and having a plan — before delivery reduces the crisis dimension when it occurs. Treatment engagement and recovery documentation are the most powerful demonstrations of parental fitness in child welfare interactions.
FREQUENTLY ASKED QUESTIONS
Can a pregnant woman go to Oceánica for treatment?
Oceánica’s program is not equipped for pregnant patients. Pregnant women with substance use disorders require specialized perinatal treatment programs with integrated obstetric care. SAMHSA’s treatment locator at findtreatment.gov identifies perinatal treatment programs in each state.
Is it safe to stop substances abruptly during pregnancy?
No — for alcohol and opioids in particular, abrupt cessation during pregnancy carries significant medical risk to both mother and fetus. Medical supervision is non-negotiable. Contact an OB/GYN and addiction medicine specialist immediately.
What is the recommended treatment for opioid use disorder during pregnancy?
Medication-Assisted Treatment with buprenorphine or methadone is the evidence-based standard of care, recommended by ACOG, ASAM, and SAMHSA. MAT produces better obstetric outcomes than either continued illicit opioid use or abrupt cessation.
What happens to the baby if I receive MAT during pregnancy?
MAT-exposed newborns may experience neonatal opioid withdrawal syndrome (NOWS), which is treatable in a hospital setting. MAT-exposed newborns generally have better outcomes than those exposed to untreated maternal addiction.
Recommended Reading
- Medical Detox in Mexico
- Mood Disorder Treatment in Mexico
- FMLA for Rehab: Your Legal Right to Leave
- Services and Programs at Oceánica
EXTERNAL REFERENCE LINKS
- SAMHSA — Pregnant Women and Substance Use
- ACOG — Opioid Use Disorder During Pregnancy
- SAMHSA Treatment Locator — Perinatal Programs
- Oceánica Conecta
Oceánica is a CARF-accredited residential treatment center in Mazatlán, Mexico. Pregnant women with substance use disorders require specialized perinatal treatment programs; Oceánica refers pregnant patients to appropriate U.S.-based programs. This article is informational and not medical advice. Do not stop substances abruptly during pregnancy without medical supervision. Call (213) 527-3377 or visit oceanica-usa.com.
